Ryan T. Muir, Sophie Stukas, Jennifer G. Cooper, Andrew E. Beaudin, Cheryl R. McCreary, Myrlene Gee, Krista Nelles, Nikita Nukala, Janina Valencia, Kristopher M Kirmess, Sandra E. Black, Michael D. Hill, Richard Camicioli, Cheryl L. Wellington, Eric. E Smith
{"title":"血浆生物标志物可区分波士顿标准 2.0 脑淀粉样变性血管病与健康对照组","authors":"Ryan T. Muir, Sophie Stukas, Jennifer G. Cooper, Andrew E. Beaudin, Cheryl R. McCreary, Myrlene Gee, Krista Nelles, Nikita Nukala, Janina Valencia, Kristopher M Kirmess, Sandra E. Black, Michael D. Hill, Richard Camicioli, Cheryl L. Wellington, Eric. E Smith","doi":"10.1101/2024.09.04.24313038","DOIUrl":null,"url":null,"abstract":"<strong>INTRODUCTION</strong> Cerebral Amyloid Angiopathy (CAA) is characterized by the deposition of beta-amyloid (Aβ) in small vessels leading to hemorrhagic stroke and dementia. This study examined whether plasma Aβ<sub>42/40,</sub> phosphorylated-tau (p-tau), neurofilament light chain (NfL) and Glial Fibrillary Acidic Protein (GFAP) differ in CAA and their potential to discriminate Boston Criteria 2.0 probable CAA from healthy controls.","PeriodicalId":501367,"journal":{"name":"medRxiv - Neurology","volume":"2013 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Plasma biomarkers distinguish Boston Criteria 2.0 cerebral amyloid angiopathy from healthy controls\",\"authors\":\"Ryan T. Muir, Sophie Stukas, Jennifer G. Cooper, Andrew E. Beaudin, Cheryl R. McCreary, Myrlene Gee, Krista Nelles, Nikita Nukala, Janina Valencia, Kristopher M Kirmess, Sandra E. Black, Michael D. Hill, Richard Camicioli, Cheryl L. Wellington, Eric. E Smith\",\"doi\":\"10.1101/2024.09.04.24313038\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<strong>INTRODUCTION</strong> Cerebral Amyloid Angiopathy (CAA) is characterized by the deposition of beta-amyloid (Aβ) in small vessels leading to hemorrhagic stroke and dementia. This study examined whether plasma Aβ<sub>42/40,</sub> phosphorylated-tau (p-tau), neurofilament light chain (NfL) and Glial Fibrillary Acidic Protein (GFAP) differ in CAA and their potential to discriminate Boston Criteria 2.0 probable CAA from healthy controls.\",\"PeriodicalId\":501367,\"journal\":{\"name\":\"medRxiv - Neurology\",\"volume\":\"2013 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-09-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"medRxiv - Neurology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1101/2024.09.04.24313038\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"medRxiv - Neurology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/2024.09.04.24313038","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Plasma biomarkers distinguish Boston Criteria 2.0 cerebral amyloid angiopathy from healthy controls
INTRODUCTION Cerebral Amyloid Angiopathy (CAA) is characterized by the deposition of beta-amyloid (Aβ) in small vessels leading to hemorrhagic stroke and dementia. This study examined whether plasma Aβ42/40, phosphorylated-tau (p-tau), neurofilament light chain (NfL) and Glial Fibrillary Acidic Protein (GFAP) differ in CAA and their potential to discriminate Boston Criteria 2.0 probable CAA from healthy controls.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
